Victor Grifols Roura announces retirement from Grifols Board of Directors; Albert Grifols Coma-Cros assumes the vacated seat

- **Mr. Grifols Roura, who through his bold vision transformed Grifols into a top worldwide manufacturer of plasma-medicines, relinquishes his seat on the company’s Board after serving on it for nearly four decades. He will continue as Chairperson of Honor**

- **Following his father’s example, Victor Grifols Roura stepped down as CEO at the age of 67, in 2017. He retired as Chairman in 2022 when he was 72, and leaves his Board seat as of today to ensure an orderly transition**

- **Mr. Grifols Roura’s vacated Board seat will be filled by Albert Grifols Coma-Cros, grandson of Josep Antoni Grifols i Lucas, the developer of the plasmapheresis technique, still the global standard for direct plasma collection in the industry**

**Barcelona, Spain Dec. 19, 2023** – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and well-being for more than 110 years, today announced that Victor Grifols Roura, grandson of the company’s founder and the man whose entrepreneurial hustle captained the company to the top tier of the plasma industry, has said he is retiring from the company’s Board of Directors.

He relinquishes his seat on the Board on which he has made his presence felt since becoming a director nearly 40 years ago, first as CEO in 1987, then continuing in 2017 with the sole title of Chairman and, from October 2022, as Chairman of Honor and proprietary director. His retirement comes exactly 50 years after joining Grifols as Export Director, beginning an illustrious career at the only corporate employer he would ever have.

“With the company once again on a sustainable growth path it’s time for me to turn the page and begin the next chapter, exceedingly proud, humble and awed by what we’ve been able to do for patients and society during the last decades,” said Mr. Victor Grifols Roura. “I am a lucky man in having been able to combine during my lifetime, as my father did during his, the two things that have been my passion, my family and my career.”

Mr. Grifols Roura was the mastermind behind Grifols’ international expansion and built consensus with his teams through the power of his convictions. When his father, Victor Grifols i Lucas, handed him the CEO reins after building the business and positioning it for global growth, Mr. Grifols Roura and his team seized the opportunity.
Five years after listing Grifols on the Spanish stock exchange in 2006, Mr. Grifols Roura engineered perhaps his most defining tour de force, the acquisition of Talecris Biotherapeutics, Inc. The daring purchase – Talecris was larger – instantly catapulted Grifols into an international leader in the plasma industry. In 2014, Mr. Grifols Roura made Grifols an instant global player in Diagnostics when he engineered the acquisition of Novartis’ transfusion medicine business unit.

He stepped down as CEO in 2017 when he was 67, the same age his father had when Victor Grifols Roura assumed the role from him 30 years earlier. This began a series of well-timed and orderly transitions in the Grifols Board and executive suite.

A tireless champion for universal access to plasma medicines and the need to increase their availability around the world, he is roundly hailed as a sector statesman. Victor Grifols Roura has received several awards. These include the 2010 Global Business Leader Award from the United States Chamber of Commerce in Spain and, one year on, Business Leader of the Year from the Spain-U.S. Chamber of Commerce. In 2017, he received a Doctor Honoris Causa from the University of Massachusetts Medical School.

Mr. Grifols Roura’s open board seat will be filled by Albert Grifols Coma-Cros, who until September 2023 was the company’s Chief Scientific Innovation Officer. He is the grandson of Josep Antoni Grifols i Lucas, the developer of the plasmapheresis technique. Since 1951, it has been the gold standard for safely and effectively collecting large amounts of plasma for subsequent manufacture into lifesaving plasma therapeutics.

“Being appointed a member of the Grifols Board is an absolute honor for me, and I look forward to being able to contribute to the company’s continued growth and leadership in the plasma sector,” said Albert Grifols Coma-Cros.

He joined Grifols in 2004 as an analyst in the company’s Planning and Control Department, before taking a similar role in the Finance Department in 2007. In 2013, he became Director of the Corporate Treasury Department, a unit he helped create. Five years later, he was named General Manager of Grifols Ireland, where he built a global plasma logistics and supply hub. In 2021, he assumed the role of Chief Scientific Innovation Officer, in which for two years he reorganized the team, established future priorities and created important partnerships with Google, Barcelona Health Hub and others to enhance how Grifols applies data and new technologies.

“Over the more than 25 years I have had the privilege and honor of calling Victor Grifols Roura my colleague and friend, he has truly been an inspiration to the organization and the global plasma community,” said Thomas Glanzmann, Grifols Executive Chairman and CEO. “We will miss his piercing intelligence, sharp wit and experienced perspective, but we know that as Chairperson of Honor he will always be there with his sound advice. I also know Albert well and I am pleased to welcome him and his unique experience and point of view to the Board.”

INVESTORS:
Grifols Investors Relations & Sustainability
inversores@grifols.com - investors@grifols.com
sostenibilidad@grifols.com - sustainability@grifols.com
Tel. +34 93 571 02 21
MEDIA CONTACTS:

<table>
<thead>
<tr>
<th>Grifols Press Office</th>
<th>Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="mailto:media@grifols.com">media@grifols.com</a></td>
<td>Duomo Comunicación</td>
</tr>
<tr>
<td>Tel. +34 93 571 00 02</td>
<td>Tel.: +34 91 311 92 89 – +34 91 311 92 90</td>
</tr>
<tr>
<td></td>
<td>Raquel Lumbreras (Tel. +34 659 572 185)</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:Raquel_lumbreras@duomocomunicacion.com">Raquel_lumbreras@duomocomunicacion.com</a></td>
</tr>
<tr>
<td></td>
<td>Borja Gómez (Tel. +34 650 402 225)</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:Borja_gomez@duomocomunicacion.com">Borja_gomez@duomocomunicacion.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>International</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finsbury Glover Hering</td>
</tr>
<tr>
<td>Email: <a href="mailto:Grifols-global@finsbury.com">Grifols-global@finsbury.com</a></td>
</tr>
<tr>
<td>Tel.: +44 20 7251 3801</td>
</tr>
</tbody>
</table>

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with more than 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols’ economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept
any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.